RAD52 and non-small cell lung carcinoma: Finally, expression studies performed on RAD52 genetic variants in lung squamous cell carcinoma (LSCC) have demonstrated that variations in RAD52 protein expression correlate with the risk of non-small cell lung cancer (NSCLC) and that RAD52 depletion increases the death of cells undergoing carcinogenic transformations and in vivo antitumoral activity [95].